19:50 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Ltd
- Share price
- ₹202.68
- Market cap
- ₹26,984 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -86.0×Sector 47.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 3Business Update 3Share Pledge 2Merger & Restructuring 2Results Update 1Regulatory Approval 1Financial Results 1Employee Stock Options 1Earnings Call 1Board Meeting Date 1Annual General Meeting 1Adverse Business Impact 1
Time
3 announcements with these filters
17:01 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.
17:29 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma has resumed operations at its Ahmedabad facility following the recent temporary suspension due to heavy rainfall. Operations are substantially restored with no material financial impact.